FLNA vs GALT

Filana Therapeutics, Inc. vs Galectin Therapeutics Inc. — Valuation Comparison 2026

FLNA

Biotechnology
Filana Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
18
SAFE
Price
$1.55
Last close
Models
8/13
Active
VS

GALT

Biotechnology
Galectin Therapeutics Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$2.57
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType FLNA Fair ValueFLNA Upside GALT Fair ValueGALT Upside
Bayesian DCF Intrinsic $1.40 -9.9% $0.80 -68.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.98 -36.6%
PWERM Option-Based $2.22 +43.4% $4.46 +73.5%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FLNA vs GALT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FLNA vs GALT — Which Stock Is More Undervalued?

FLNA scores higher with a 4.5/10 quality rating vs GALT's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Filana Therapeutics, Inc. (FLNA) and Galectin Therapeutics Inc. (GALT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FLNA currently trades at $1.55 with a QOC of 4.5/10, while GALT trades at $2.57 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).